Isosorbide dinitrate
Based on 1 Customer Validation
Isosorbide dinitrate (ISDN) is an NO donor that prevents LV remodeling and degradation of cardiac function following myocardial infarction (MI).
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 87-33-2
- Formula: C6H8N2O8
- Molecular Weight:236.14
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 143B | CC50 |
0.0006 M
Compound: ISDN
|
In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
|
[PMID: 12620076] |
| 143B | CC50 |
0.0007 M
Compound: ISDN
|
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
|
[PMID: 12620076] |
| 143B | CC50 |
0.6 mM
Compound: ISDN
|
In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
|
[PMID: 12620076] |
| 143B | CC50 |
0.7 mM
Compound: ISDN
|
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
|
[PMID: 12620076] |
| 143B | CC50 |
0.007 M
Compound: ISBN
|
In vitro cell cytotoxicity was determined against 143B cell line
In vitro cell cytotoxicity was determined against 143B cell line
|
[PMID: 15027876] |
| 143B | CC50 |
0.0074 M
Compound: ISBN
|
In vitro cell cytotoxicity was determined against 143B-LTK cell line
In vitro cell cytotoxicity was determined against 143B-LTK cell line
|
[PMID: 15027876] |
| EMT6 | CC50 |
0.00038 M
Compound: ISBN
|
In vitro cell cytotoxicity was determined against EMT-6 cell line
In vitro cell cytotoxicity was determined against EMT-6 cell line
|
[PMID: 15027876] |
| EMT6 | CC50 |
0.38 mM
Compound: ISBN
|
In vitro cell cytotoxicity was determined against EMT-6 cell line
In vitro cell cytotoxicity was determined against EMT-6 cell line
|
[PMID: 15027876] |
| KBALB cell line | CC50 |
0.97 mM
Compound: ISDN
|
In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line)
In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line)
|
[PMID: 12620076] |
| KBALB-STK | CC50 |
0.00065 M
Compound: ISDN
|
In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK
In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK
|
[PMID: 12620076] |
| KBALB-STK | CC50 |
0.65 mM
Compound: ISDN
|
In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK
In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK
|
[PMID: 12620076] |
| KBALB-STK | CC50 |
6.5 x 10-4 M
Compound: ISDN
|
In vitro cell cytotoxicity was determined against KBALB-STK cell line
In vitro cell cytotoxicity was determined against KBALB-STK cell line
|
[PMID: 15027876] |
Isosorbide dinitrate postconditioning exhibits a cardioprotective effect against rat myocardial ischemia-reperfusion injury in vivo[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5–6 weeks old male juvenile Sprague-Dawley rats (200–250 g)[1]
-
Dosage:3 mg/kg
-
Administration:Intratracheal; for 13 days following coronary ligation
-
Result:Reduced MI size and alleviated left and right ventricular remodeling following MI.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 87-33-2
-
Appearance Solid
-
Molecular Weight 236.14
-
Formula C6H8N2O8
-
Color White to off-white
-
SMILES
[H][C@]12OC[C@H](O[N+]([O-])=O)[C@]1(OC[C@H]2O[N+]([O-])=O)[H]
-
Synonyms
ISDN
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (423.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.81 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang X , et al. Intratracheal administration of isosorbide dinitrate improves pulmonary artery pressure and ventricular remodeling in a rat model of heart failure following myocardial infarction. Exp Ther Med. 2017 Aug;14(2):1399-1408. [Content Brief]
[2]. Zhao X, et al. Cardioprotective Effect of Isosorbide Dinitrate Postconditioning Against Rat Myocardial Ischemia-Reperfusion Injury In Vivo. Med Sci Monit. 2019 Mar 2;25:1629-1636. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.2348 mL | 21.1739 mL | 42.3478 mL | 105.8694 mL |
| 5 mM | 0.8470 mL | 4.2348 mL | 8.4696 mL | 21.1739 mL | |
| 10 mM | 0.4235 mL | 2.1174 mL | 4.2348 mL | 10.5869 mL | |
| 15 mM | 0.2823 mL | 1.4116 mL | 2.8232 mL | 7.0580 mL | |
| 20 mM | 0.2117 mL | 1.0587 mL | 2.1174 mL | 5.2935 mL | |
| 25 mM | 0.1694 mL | 0.8470 mL | 1.6939 mL | 4.2348 mL | |
| 30 mM | 0.1412 mL | 0.7058 mL | 1.4116 mL | 3.5290 mL | |
| 40 mM | 0.1059 mL | 0.5293 mL | 1.0587 mL | 2.6467 mL | |
| 50 mM | 0.0847 mL | 0.4235 mL | 0.8470 mL | 2.1174 mL | |
| 60 mM | 0.0706 mL | 0.3529 mL | 0.7058 mL | 1.7645 mL | |
| 80 mM | 0.0529 mL | 0.2647 mL | 0.5293 mL | 1.3234 mL | |
| 100 mM | 0.0423 mL | 0.2117 mL | 0.4235 mL | 1.0587 mL |
Isosorbide dinitrate Related Classifications
HY-B1409 Related Classifications
Powered by Bioz